Hologic to Webcast Presentations at Upcoming Investor Conferences

May 21, 2024 | Last Trade: US$70.70 0.49 -0.69

MARLBOROUGH, Mass. / May 21, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:

2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on Wednesday, May 29^th at 10 a.m. Central Time (CT).
William Blair 44^th Annual Growth Stock Conference in Chicago, Illinois on Tuesday, June 4^th at 8:40 a.m. CT.

Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcasts will be available for 30 days following each event.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Stock Quote

Last Trade:	US$70.70
Daily Change:	-0.49 -0.69
Daily Volume:	1,225,369
Market Cap:	US$15.960B

January 12, 2025 Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025 December 18, 2024 Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC December 09, 2024 Hologic: New Data To Be Presented at SABCS 2024 Investigates the Potential Role of the Breast Cancer Index® Test in Identifying Patients With Minimal Risk of Distant Recurrence December 09, 2024 Martin Madaus Elected to Hologic Board of Directors December 02, 2024 Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations LOAD MORE NEWS

Featured Stock

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE